1. Introduction {#sec1}
===============

Colorectal cancer (CRC) is the third most common cancer in men and the second in women worldwide. In the latest worldwide estimates of cancer incidence in 2018, there were over a million cases of colon cancer and about 700.000 cases of rectal cancer in both men and women \[[@B1]\]. However, incidence rates of colorectal carcinoma vary significantly in different areas. According to the Jordan National Cancer Registry (JNCR) report in 2016, there were 641 colorectal cancer cases, accounting for 10.7% of all newly diagnosed cases among Jordanians. It ranked the second among all new cancers in both genders, the first among males and the second among females \[[@B2]\].

With a median age of 68 years in men and 72 in women for colon cancer and 63 years for rectal cancer in both men and women, and as CRC incidence increases significantly beyond the fifth decade of life, screening is usually not recommended for individuals at an average risk younger than 45 years \[[@B3], [@B4]\]. However, an increase in the incidence of CRC in younger adults has been witnessed recently, with reports from USA suggesting that approximately 11% of colon cancers and 18% of rectal cancers occur in individuals younger than the age of 50 \[[@B5]--[@B7]\]. Furthermore, in contrast to the noticed decline in CRC mortality among adults aged 55 years and older, there is about 11% increase in mortality among adults younger than 55 years \[[@B4]\].

Numbers suggest a possible high incidence of CRC in young Jordanian patients, with 102 of CRC diagnosed cases (16%) at the age of 44 years or younger in the most recent registry data in 2014 \[[@B2]\]. At King Hussein Cancer Center, 688 out of 1902 (36.2%) patients diagnosed with CRC were younger than 45 years during the same time period (unpublished data).

Colorectal carcinoma occurs sporadically in the majority of cases. Twenty--30% of all CRCs appear to have a familial basis, and only 5%--10% are due to inherited mutations in well-known cancer-related genes. Recognized hereditary conditions include familial adenomatous polyposis (FAP) syndrome, nonpolyposis hereditary colorectal carcinoma (NPHCC) syndrome, or Lynch syndrome, MUTYH-associated polyposis, and certain hamartomatous polyposis conditions. These syndromes can predispose individuals to the development of CRC at a higher frequency and at a younger age \[[@B8]\].

Hereditary nonpolyposis colorectal cancer (Lynch syndrome)---an autosomal dominant syndrome---is the most common form of hereditary colorectal cancer. It accounts for 2--4% of all colorectal cancers \[[@B9]\], and the lifetime risk for development of CRC is 25--75% \[[@B10]\]. Research showed that individuals from the general population have a 2% lifetime risk of developing CRC, whereas the risk for patients with Lynch syndrome is over 80% \[[@B11]\]. In families with Lynch syndrome, CRC is frequently diagnosed at a younger age and progress more rapidly. About one fourth of family members develop CRC by the age of 50. Adenomatous polyps in affected individuals can progress to invasive cancer within 30 months compared to 10 years in the general population \[[@B12]\]. Extracolonic malignancies associated with Lynch syndrome include endometrial, gastric, ovarian, biliary, urinary tract, small bowel, brain, and pancreatic cancer among others \[[@B13]\]. The most common is endometrial carcinoma, where women affected by the syndrome have up to a 71% lifetime risk of developing endometrial cancer, compared to 1.5% lifetime risk in the general population \[[@B11]\]. Accordingly, detailed criteria have been developed to identify patients with Lynch syndrome including the Amsterdam Criteria, the Bethesda Guidelines, and the revised Bethesda Guidelines \[[@B14]\]. Young age at onset is usually included among the indicators of an inherited CRC syndrome. Therefore, when dealing with an early onset CRC patient, testing for the possibility of Lynch syndrome is warranted.

The hallmark of tumors in Lynch syndrome is microsatellite instability (MSI). Microsatellites are genomic regions in which mutation can occur during DNA replication. These mutations are usually repaired by the mismatch repair proteins(MMRP) \[[@B9]\]. The mechanism of development of CRC in Lynch syndrome is related to germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, PMS2, MSH2, or MSH6 \[[@B10]\]. A cost-effective approach for identifying Lynch syndrome is to perform tumor testing when any of the Bethesda guidelines are identified. The most commonly used method is to begin with MSI and/or immunohistochemistry (IHC) analysis of CRC. Applying immunohistochemical stains on paraffin-embedded tumor tissue sections to look for mutations in one or more of the MMRPs, including MLH1, PMS2, MSH2, and MSH6 proteins, is an easy and convenient method to test for the mutations in tumors associated with loss or inactivation of the relevant mismatch repair gene. The sensitivity of IHC is comparable to that of MSI analysis, with the advantage of direct genetic testing to the appropriate MMR gene when loss of MMRP expression is identified \[[@B15]\]. Additionally, the same method can be used as a screening tool for colorectal cancer patients. The finding of an abnormal MMRP expression in an adenomatous polyp from a patient with a concerning family history could provide justification for formal genetic evaluation \[[@B16]\]. Of note, MSI is detected in about 15% of all CRCs; 3% of these are associated with Lynch syndrome, and the other 12% are caused by sporadic, acquired hypermethylation \[[@B17]\].

In this study, we investigate the prevalence of dMMRP in young patients with CRC and describe patients\' and tumors\' characteristics and outcome in comparison to pMMRP tumors in the same age group.

2. Materials and Methods {#sec2}
========================

This study targeted cases of CRC diagnosed and treated at the King Hussein Cancer Center from 2004 until 2012 in patients 45 years of age or younger at the time of diagnosis. After obtaining the Institutional Review Board approval, all patients\' charts were reviewed. The clinical data including the age at diagnosis, the presenting symptoms and signs, family history of colorectal cancer or other types of cancer, the location, stage, and the treatment modality as well as the event-free survival (EFS) and overall survival (OS) were collected.

The pathology slides for the CRC resection specimens were reviewed. Slides containing the tumor and normal tissue and their corresponding paraffin blocks were retrieved when available; otherwise, the biopsy blocks were used instead.

Immunohistochemistry analysis was performed using the following monoclonal antibodies: anti-MLH-1 (clone M1, Roche), anti-MSH2 (clone G219-1129, Roche), anti-MSH6 (clone 44, Roche), anti-PMS2 (clone EPR3947, Roche), and P53 (clone DO7, Roche). Staining was performed using the automated tissue staining system (immunostainer BenchMark ULTRA (Ventana Medical systems, Inc.)) using validated protocols. Testing for PMS2 and MSH6 was done first \[[@B18]\]. Only cases with aberrant expression of PMS2 and/or MSH6 were tested for MLH1 and/or MSH2, respectively. Aberrant expression was considered when the tumor showed loss of nuclear staining for any of the MMRP, in the presence of an internal positive control (endothelium or lymphocytes). Two pathologists (B. M and M. H) assessed all cases independently. The few cases with discrepant scoring were reevaluated jointly, and agreement was reached in all cases.

Structured spreadsheets for data collection and Access Database were developed to assist reviewing and documenting epidemiological and clinical factors including follow-up and survival data. Descriptive statistics using frequencies and percentages were applied. Univariate analysis was performed using the Student *t*-test for continuous variables, and the differences in proportions were tested with the *χ*^2^ (Chi-square) or Fisher exact test. Multivariate correlation analysis was performed using the logistic regression test.

The Kaplan-Meier method was adopted to estimate EFS and OS curves, and the log-rank test was used to compare patients\' survival times. The OS was calculated from the primary diagnosis to death from any cause; patients who were alive at the last follow-up were censored at that time. The EFS was calculated from the primary diagnosis to the first event (relapse or death). Survival was expressed as median with a 95% confidence interval. A significance criterion of *p* ≤ 0.05was used in the analysis. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

3. Results {#sec3}
==========

A total of 155 cases with available paraffin blocks were included in the study. The median age at diagnosis was 38 years (range from 17 to 45 years). Eighty three (54%) patients were male, and male to female ratio was 1.15 : 1. Most tumors included in the study were located in the rectum (47%), with 15%, 11%, and 25% located in the right, left, and sigmoid colon, respectively. Most tumors were advanced at the time of diagnosis, with approximately 70% presenting at stage III and IV disease. The main histopathological features of the tumors were as follows: 132 patients (85.2%) had well-moderately differentiated adenocarcinoma, 23 (14.8%) patients had poorly differentiated adenocarcinoma, and 27 (17.4%) patients had mucinous carcinoma. The clinicopathological features are summarized in [Table 1](#tab1){ref-type="table"}.

A total of 29 (19%) cases were dMMRP. Loss of expression of PMS2 was seen in 17 cases, 12 of which showed loss of MLH1 expression. Additionally, loss of expression of MSH6 was seen in 10 cases, 9 of which showed loss of MSH2 expression. One case showed loss of all four MMR proteins, and another case showed loss of PMS2/MLH1 and MSH6. [Table 2](#tab2){ref-type="table"} summarizes the characteristics of individual patients with mismatch repair deficiency. Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} show examples of the MLH1/PMS2 and MSH2/MSH6 loss of nuclear staining, respectively.

There was a significant association between dMMRP and tumor location proximal to splenic flexure, as well as the pathologic features suggestive of MSI (mucinous component, tumor-infiltrating lymphocytes (TIL), and Crohn\'s-like lymphocytic reaction (CLR)). MMRP-deficient tumors presented significantly at a lower stage and with negative nodal metastasis. About 86% of dMMRP cases were negative for P53 which was statistically significant (*p* value = 0.000). [Table 3](#tab3){ref-type="table"} presents the relationship between the dMMRP tumors and the various clinicopathological features. Interestingly, loss of MSH2/MSH6, but not MLH1/PMS2, was significantly associated with positive family history in first- and/or second-degree relatives (*p* value = 0.020). On multivariate analysis, right-sided location, pathologic features suggestive of MSI, P53 negativity, early stage, and survival status remained significantly associated with dMMRP ([Table 4](#tab4){ref-type="table"}).

The Kaplan-Meier survival curves of patients with dMMR or pMMR indicated a significantly better OS but not EFS in patients with dMMR (*p* value 0.0250 and 0.0693, respectively) ([Figure 3](#fig3){ref-type="fig"}).

4. Discussion {#sec4}
=============

In Jordan, colorectal cancer replaced lung cancer as the most common cancer in men and the second most common cancer in women. The rates of colorectal cancer increased significantly in Jordan which may be attributed to changes in diet habits and the westernization of the lifestyle \[[@B19], [@B20]\]. Additionally, Tamwneh et al. reported a low rate of colorectal cancer under 40 years of age in Jordan between 1996 and 2005, after which the rates began to rise steadily, with rates of 18.7 and 24.3 per 100 000 poplutation for males and females, respectively, by the age of 40--59 years \[[@B20]\]. After this period reports from Jordan cancer registry showed increased trends of age-specific incidence rates (ASIR) and age-standardized incidence rates (ASR) for colorectal cancer \[[@B2]\].

Rectal cancer is far more common than colonic cancer. According to the Jordan National Cancer Registry during the period of the study(2004-2012), there were a total of 4453 colorectal cancer cases, 35.0% of which were in the rectum \[[@B2]\]. Additionally, rectal carcinoma accounted for 37.8% (*n* = 719) out of 1902 CRC patients over the same time period at KHCC (unpublished data). We included 155 cases in this study of which around 47% were located in the rectum. This finding may suggest that CRC in young individuals have a predilection for the distal colon, regardless of MMRP status. A Similar finding was previously reported by Goel et al. \[[@B21]\].

Studies of colorectal carcinogenesis suggest that molecular events which lead to colonic adenocarcinoma are heterogeneous and include genetic and epigenetic abnormalities. The commonest genetic pathways described are the APC/*β*-catenin pathway and the MSI pathway, which are associated with defects in DNA mismatch repair and accumulation of mutations in microsatellite repeat regions of the genome. Epigenetic events via methylation-induced gene silencing may enhance progression along either pathways \[[@B22]\].

Several studies addressed the frequency of MMRP deficiency either by IHC and molecular studies or by IHC alone. Such studies reported a highly variable prevalence of MMRP deficiency, probably attributed to differences in the cut-off age and methods of screening used. When taking the age into account, the rate of MMRP deficiency reported in this study (19%) is comparable with that of other studies that examined the prevalence of dMMRP among young patients (\<50 years old) \[[@B21], [@B23]--[@B25]\]. In the Middle East region, however, Ashktorab et al. reported a rate of 16.3% dMMRP by IHC in Omani subjects \[[@B26]\]. Using MSI as the initial screening test, a study from Saudi Arabia reported 11.6% MSI cases \[[@B27]\]. In the Iranian population, 10.57% of the early-onset CRCs were dMMRP \[[@B28]\]. A low frequency (8.4%) of dMMRP was reported in a study from Japan \[[@B29]\], which was the first to evaluate the prevalence of dMMRP in CRC in the young Japanese population, suggesting that this low rate might be related to yet-to-be identified genetic or environmental factors.

Histologic features of MSI-H are defined as the presence of tumor-infiltrating lymphocytes, Crohn\'s-like lymphocytic reaction, and mucinous differentiation \[[@B30]\] and are well described in the literature. Analysis of the relationship between dMMRP and these features showed significant association in our study. Sporadic MSI-H CRCs are also known to be characterized by eosinophilic tumor cells (ETC) \[[@B31]\]; however, our study failed to show a significant association.

As this study sample included early-onset CRC cases, it should be expected to include sporadic as well as familial cases. Sporadic dMMRP cases are often associated with hypermethylation of the promoter region of the MLH1 with resultant silencing of MLH1 gene and absent protein expression by IHC \[[@B22]\]. In keeping with this idea and since sporadic dMMRP CRC cases constitute a major proportion of patients, our study showed loss of MLH1 as the most common pattern of dMMRP tumors accounting for 41% of cases. Conversely, loss of expression of MSH2, MSH6, or PMS2 in isolation is considered a strong evidence of a germline mutation in the respective gene \[[@B32]\]. Of these, MSH2 is the most commonly mutated in Lynch syndrome accounting for 41% of cases \[[@B33]\]. The current study showed loss of MSH2 in 30%, isolated MSH6 in 3%, and isolated PMS2 in 17% of dMMRP cases. Notably, there were no cases of constitutional mismatch deficiency in our study. This is defined by loss of staining of MMRP in tumor cells as well as normal tissue. Individuals with this pattern have biallelic germline mutations in MMR genes \[[@B34]\]. Moreover, only loss of MSH2/MSH6 showed a significant association with positive family history (*p* value = 0.020) supporting the idea of germline mutation.

Univariate analysis showed a significant association between tumor location proximal to splenic flexure (i.e., right-sided location) and MMRP deficiency. This association remains significant also on the multivariate analysis with an odds ratio of 5.462. This finding is well documented and aligned with the literature \[[@B21], [@B25], [@B29], [@B35]--[@B38]\].

We found that dMMRP tumors tended to present at an earlier stage in consistency with several previous studies of MMRP-deficient colorectal cancer \[[@B25], [@B35], [@B37], [@B39]\]. In this study, there was no significant association between the stage of the primary tumor (T stage) or distant metastasis (M stage) and MMRP deficiency. However, a significant association was seen in nodal status, with dMMRP cases tending to have less nodal metastasis than pMMRP cases (*p* value = 0.035). This low frequency of lymph node involvement is the characteristics of dMMRP \[[@B38]\]. Multivariate analysis confirmed that dMMRP cases have a lower rate of stage III disease when compared to stages I and II with odds ratio (4.587; 95% CI (confidence interval), 1.190-17.685; *p* = 0.0269).

In multivariate analysis, another variant that remained significant is the P53 status, with the tendency of dMMRP cases to be P53 negative \[[@B40], [@B41]\].

At the last available follow-up, 19 out of the 29 dMMR cases (66%) were alive without disease, 1 (3%) was alive with metastasis, and 9 (31%) were dead of disease. The Kaplan-Meier survival curves showed a significantly better OS in dMMRP compared to pMMRP patients, consistent with previously described outcome \[[@B37], [@B42], [@B43]\].

We acknowledge limitations in this study including the retrospective nature of the data, with all patients collected from a single cancer center, which might induce referral bias. Also, we did not perform germline mutational analysis to confirm patients with Lynch syndrome. However, this study sheds light on the frequency of dMMRP in young patients with CRC in our population. Our findings including the suggestive microscopic features,the better outcome and the lower stage are consistent with the international literature. In a country with limited resources, but with a prevalence of CRC in the young as frequent as in western countries, testing for MMRP by a cost-effective method like IHC is recommended. Further confirmatory testing, genetic counselling, and surveillance for the patient and family members can be guided by these results.
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![Immunohistochemical staining for mismatch repair proteins. (a) Moderately differentiated adenocarcinoma (H&E ×400). (b) PMS-2 immunostain shows retained nuclear staining in the tumor (×400). (c) MSH-6 immunostain shows loss of nuclear staining in the tumor, while it is retained in infiltrating lymphocytes (×400). (d) MSH2 also shows loss of nuclear staining in the tumor (×400).](GRP2020-5632984.001){#fig1}

![Immunohistochemical staining for mismatch repair proteins. (a) Moderately differentiated adenocarcinoma (H&E ×400). (b) PMS-2 immunostain shows loss of nuclear staining in the tumor, while it is retained in infiltrating lymphocytes (×400). (c) MLH-1 immunostain shows loss of nuclear staining in the tumor, while it is retained in infiltrating lymphocytes (×400). (d) MSH-6 immunostain is retained in tumor cell nuclei (×400).](GRP2020-5632984.002){#fig2}

![Survival curves for overall survival (a) and event-free survival (b) in patients with dMMRP vs. patients with pMMRP colorectal carcinoma.](GRP2020-5632984.003){#fig3}

###### 

Clinicopathological criteria of patients with colorectal cancer.

  Clinicopathological features                *N*   \%
  ------------------------------------------- ----- -------
  Gender                                            
   Male                                       83    53.5%
   Female                                     72    46.5%
  Age (years) classification                        
   20 or less                                 1     0.6%
   21-25                                      4     2.6%
   26-30                                      12    7.7%
   31-35                                      37    23.9%
   36-40                                      56    36.1%
   41-45                                      45    29.0%
   Median age                                 38    
  Location                                          
   Right colon                                23    14.8%
   Transverse colon                           3     1.9%
   Left colon                                 17    11.0%
   Sigmoid                                    39    25.2%
   Rectum                                     73    47.1%
  Histologic features                               
   Well-differentiated adenocarcinoma         4     2.6%
   Moderately differentiated adenocarcinoma   128   82.6%
   Poorly differentiated adenocarcinoma       23    14.8%
   Mucinous component                         27    17.4%
   Lymphovascular invasion                    55    35.5%
   Eosinophilic tumor cells                   10    6.5%
  TNM stage groupings                               
   I                                          12    7.7%
   II                                         35    22.6%
   III                                        67    43.2%
   IV                                         41    26.5%

###### 

Characteristics of individual patients with mismatch repair deficiency.

       Age (Yr)   Gender   Family history       Tumor location   Stage   Grade   Pathological feature suggestive of MSI   Specific pathologic pattern   Pattern of MMR loss   Outcome
  ---- ---------- -------- -------------------- ---------------- ------- ------- ---------------------------------------- ----------------------------- --------------------- ---------
  1    43         M        NA                   Ascending        I       II      Yes                                      TIL, CLR                      MLH1/PMS2             AWD
  2    44         M        No                   Sigmoid          III     II      Yes                                      CLR                           MLH1/PMS2             AWD
  3    42         F        Yes (1^st^ degree)   Sigmoid          III     II      Yes                                      TIL, CLR                      MLH1/PMS2             AWD
  4    42         F        No                   Rectum           III     II      Yes                                      CLR                           MLH1/PMS2             AWD
  5    44         M        Yes (1^st^ degree)   Rectum           I       II      No                                       ---                           MSH2/MSH6             AWD
  6    42         M        No                   Ascending        III     II      No                                       ---                           MLH1/PMS2             AWD
  7    34         M        Yes (2^nd^ degree)   Sigmoid          II      II      Yes                                      TIL, CLR                      MSH2/MSH6             AWD
  8    35         M        Yes (1^st^ degree)   Rectum           I       II      Yes                                      CLR                           MSH2/MSH6             AWD
  9    33         M        NA                   Ascending        II      II      Yes                                      Mucinous, TIL, CLR            PMS2                  AWD
  10   39         M        NA                   Ascending        II      II      Yes                                      Mucinous                      MSH2/MSH6             AWD
  11   34         M        NA                   Ascending        IV      II      Yes                                      Mucinous, TIL, CLR, ETC       MLH1/PMS2             AWMD
  12   38         F        No                   Rectum           IV      III     Yes                                      Mucinous                      PMS2                  DOD
  13   30         M        Yes (1^st^ degree)   Transverse       III     III     Yes                                      TIL, CLR, ETC                 MSH2/MSH6             DOD
  14   40         M        NA                   Rectum           II      II      Yes                                      Mucinous                      MLH1/PMS2             DOD
  15   30         F        NA                   Descending       IV      II      No                                       ---                           PMS2                  DOD
  16   36         F        No                   Sigmoid          II      II      No                                       ---                           PMS2                  AWD
  17   35         M        Yes (2^nd^ degree)   Rectum           IV      II      No                                       ---                           MLH1/PMS2             DOD
  18   37         F        No                   Ascending        II      II      Yes                                      CLR                           MLH1/PMS2             DOD
  19   40         M        Yes (1^st^ degree)   Ascending        IV      II      Yes                                      Mucinous                      MSH2/MSH6             DOD
  20   33         M        Yes (2^nd^ degree)   Ascending        II      II      No                                       ---                           All 4                 AWD
  21   34         F        Yes (1^st^ degree)   Ascending        II      II      No                                       ---                           MSH2/MSH6             AWD
  22   37         M        No                   Sigmoid          II      II      Yes                                      TIL                           MSH6                  AWD
  23   38         F        Yes (1^st^ degree)   Ascending        III     II      Yes                                      Mucinous                      MLH1/PMS2             AWD
  24   37         M        No                   Descending       IV      III     Yes                                      Mucinous                      MLH1/PMS2             DOD
  25   26         F        No                   Descending       II      I       Yes                                      CLR                           MSH2/MSH6             AWD
  26   37         M        No                   Descending       III     III     Yes                                      Mucinous                      PMS2                  DOD
  27   36         F        NA                   Ascending        II      II      Yes                                      CLR                           MLH1/PMS2             AWD
  28   37         M        NA                   Descending       II      II      Yes                                      CLR                           MLH1/PMS2 and MSH6    AWD
  29   37         M        NA                   Rectum           III     I       Yes                                      Mucinous                      MSH2/MSH6             AWD

Abbreviations: Yr: year; M: male; F: female; NA: not available; TIL: tumor infiltrating lymphocytes; CLR: Crohn\'s-like reaction; AWD: alive without disease; DOD: dead of disease; AWMD: alive with metastatic disease.

###### 

Relationship between the status of MMRP expression and the clinicopathological features of colon cancer.

  -----------------------------------------------------------------------------------------------------------------
  Clinicopathological features                           Total cases (*n*)   dMMRP\       pMMRP\        *p* value
                                                                             *n* (%)      *n* (%)       
  ------------------------------------------------------ ------------------- ------------ ------------- -----------
  Gender                                                                                                

   Male                                                  83                  19 (65.5%)   64 (50.8%)    0.152

   Female                                                72                  10 (34.5%)   62 (49.2%)    

  Age                                                                                                   

   17-38                                                 83                  20 (69.0%)   63 (50.0%)    0.065

   39-45                                                 72                  9 (31.0%)    63 (50.0%)    

  Neo/adj_treatment                                                                                     

   Yes                                                   31                  1 (3.4%)     30 (23.8%)    0.010

   No                                                    124                 28 (96.6%)   96 (76.2%)    

  Location                                                                                              

   Proximal to splenic flexure                           26                  12 (41.4%)   14 (11.1%)    0.000

   Distal to splenic flexure                             129                 17 (58.6%)   112 (88.9%)   

  Degree of differentiation                                                                             

   Well-moderately differentiated (I and II)             132                 25 (86.2%)   107 (84.9%)   1.000

   Poorly undifferentiated adenocarcinoma (III and IV)   23                  4 (13.8%)    19 (15.1%)    

  Pathologic features suggestive of MSI                                                                 

   Present                                               62                  22 (75.9%)   40 (31.7%)    0.000

   Absent                                                93                  7 (24.1%)    86 (68.3%)    

  Mucinous component                                                                                    

   Present                                               27                  10 (34.5%)   17 (13.5%)    0.007

   Absent                                                128                 19 (65.5%)   109 (86.5%)   

  Tumor infiltrating lymphocytes (TIL)                                                                  

   Present                                               18                  7 (24.1%)    11 (8.7%)     0.020

   Absent                                                137                 22 (75.9%)   115 (91.3%)   

  Crohn\'s-like reaction (CLR)                                                                          

   Present                                               29                  14 (50.0%)   15 (14.0%)    0.000

   Absent                                                106                 14 (50.0%)   92 (86.0%)    

   Cannot be determined^∗^                               20                                             

  Eosinophilic tumor cells (ETC)                                                                        

   Present                                               10                  2 (6.9%)     8 (6.3%)      1.000

   Absent                                                145                 27 (93.1%)   118 (93.7%)   

  P53 status                                                                                            

   Positive                                              85                  4 (13.8%)    81 (64.8%)    0.000

   Negative                                              69                  25 (86.2%)   44 (35.2%)    

  Vascular invasion                                                                                     

   Present                                               55                  8 (28.6%)    47 (42.0%)    0.194

   Absent                                                85                  20 (71.4%)   65 (58.0%)    

   Cannot be determined^∗^                               15                                             

  T stage                                                                                               

   Tx                                                    10                  1 (3.4%)     9 (7.1%)      0.784

   T1/T2                                                 19                  4 (13.8%)    15 (11.9%)    

   T3/T4                                                 126                 24 (82.8%)   102 (81.0%)   

  Node status                                                                                           

   Nx                                                    11                  1 (3.4%)     10 (7.9%)     0.035

   N0                                                    49                  15 (51.7%)   34 (27.0%)    

   N1/N2                                                 95                  13 (44.8%)   82 (65.1%)    

  M stage                                                                                               

   M0                                                    114                 23 (79.3%)   91 (72.2%)    0.435

   M1                                                    41                  6 (20.7%)    35 (27.8%)    

  TNM stage groupings                                                                                   

   I and II                                              47                  15 (51.7%)   32 (25.4%)    0.020

   III                                                   67                  8 (27.6%)    59 (46.8%)    

   IV                                                    41                  6 (20.7%)    35 (27.8%)    

  Outcome                                                                                               

   Alive                                                 78                  20 (69.0%)   58 (46.0%)    0.026

   Dead                                                  77                  9 (31.0%)    68 (54.0%)    

  Family history of cancer                                                                              

   Present (1^st^ and/or 2^nd^ degree)                   52                  10 (50.0%)   42 (42.4%)    0.533

   Absent                                                67                  10 (50.0%)   57 (57.6%)    

   Cannot be determined^∗∗^                              36                                             
  -----------------------------------------------------------------------------------------------------------------

^∗^Cases were evaluated on biopsy specimen in which these particular characteristics could not be determined. ^∗∗^Family history was not available for these cases.

###### 

Multivariate analysis of relationship between deficient mismatch repair and clinico-pathological features of colon cancer.

  Effect                                Odds ratio   95% Wald confidence limits   *p* value   
  ------------------------------------- ------------ ---------------------------- ----------- --------
  Neo-adjuvant treatment (no vs. yes)   5.429        0.530                        55.576      0.1540
  Location (right vs. left sided)       5.462        1.469                        20.313      0.0113
  Pathologic features (yes vs. no)      12.048       3.413                        41.667      0.0001
  P53 status (negative vs. positive)    18.591       3.830                        90.251      0.0003
  Stage (III vs. "I and II")            4.587        1.190                        17.685      0.0269
  Stage (IV vs. "I and II")             0.348        0.053                        2.293       0.2727
  Status (alive vs. dead)               9.052        1.855                        44.173      0.0065

[^1]: Academic Editor: Vincenzo Pilone
